NHS England consults on plans for a sustainable Cancer Drugs Fund
NHS England is proposing changes to the way its Cancer Drugs Fund (CDF) operates, in order that it delivers maximum benefit for patients, within the resources available.
and cancer specialists believe the changes, if adopted, would:
- improve patient access to
the most clinically effective drugs available through the fund;
- encourage pricing that
delivers value for money for patients and the public; and
- put the fund on a much
firmer footing for the future, as it faces increasing demand and growing
England will publicly consult for four weeks on a number of proposals, which
include – for the first time – the consideration of the cost of cancer drugs,
when deciding whether a drug should be available or not on the national cancer
drug fund list.
consultation, which opened last Friday, follows NHS England’s announcement in August
of a £160m boost for the CDF over two years.
extra funding will go some way to supporting the future sustainability of the
fund, clinicians and cancer specialists were clear that effective new
treatments could only be added to the national list, if drugs of limited
clinical benefit were removed.
of the current list of drugs is just one of the proposed changes to the fund’s
Standard Operating Procedure.
Find out more about the proposals for change, and how you
can contribute your views.